AstraZeneca unveiled plans to invest $50 billion in U.S. manufacturing and research operations through 2030, over a 14-fold increase from previous commitments. Key components include constructing the company's largest manufacturing facility in Virginia focused on small molecules and oligonucleotides, supporting metabolic and weight management drugs. This U.S. expansion aims to increase the U.S. share of AstraZeneca's revenue from 42% to 50% by 2030. CEO Pascal Soriot emphasized the importance of American innovation and securing pharmaceutical supply chains amidst looming tariff threats.